NCT04054479

Penehyclidine for PONV Prophylaxis After Strabismus Surgery

The Effect of Penehyclidine on Postoperative Nausea and Vomiting After Strabismus Surgery

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 228 (actual)
• Sponsor: The First Affiliated Hospital with Nanjing Medical University · Academic / Other
• Sex: All
• Age: 3 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Patients scheduled for elective strabismus surgery under general anesthesia in the First Affiliated Hospital of Nanjing Medical University will be included in this study. Patients 1)ASA I or II, 2)aged 3-65 years, 3)scheduled for elective strabismus surgery under general anesthesia, will be included in the study. Patients 1)had prior PONV, 2)severe motion sickness, 3)a history of ophthalmic surgery, 4)had received drugs known to have antiemetic effects, will be excluded from the study. The primary aim is to evaluate the prophylaxis effect of penehyclidine(a novel long acting selective anticholinergic agent developed in China) on postoperative nausea and vomiting after strabismus surgery. Secondary outcomes include the effect of PONV risk factors and surgical technique on PONV rank score, occurance of oculocardiac reflex, time to extubation.

Conditions

• PONV

Interventions

Type	Name	Description
DRUG	Penehyclidine	Patients receive penehyclidine 10μg/kg(up to 0.5mg, diluted with normal saline to 0.1mg/ml) after anesthesia intubation.
DRUG	normal saline	Patients receive 0.1ml/kg normal saline(up to 5ml) after anesthesia intubation.

Timeline

• Start date: 2019-07-20
• Primary completion: 2019-07-22
• Completion: 2019-11-01
• First posted: 2019-08-13
• Last updated: 2019-12-17

Locations

1 site across 1 country: China